Would you like to know if you are eligible for the Neridronate Treatment? Book your free video call now!

CRPS Treatment: pain in leg for 8 months

General details and patient's info

Age:24 years old at the time of first treatment, 25 at the time of second treatment.
Home Country:United States of America.
Illness duration:8 months prior to the first Neridronate Treatment.
Cause:Lifting accident.
Symptoms:The right leg is colder than the left one, it shows changes in color, skin texture and nail growth. Swollen, very sensitive to touch and temperature changes, spasms, difficulty to move toes, stiffness. Burning pain, much worse with movement and pressure. Constant pain, worse in the afternoon and evening after activities. Needs wheelchair occasionally.
Clinical evaluation:CRPS diagnosis, with radial nerve damage. Unable to fully extend the left hand. Mild generalized soft tissues edema of the elbow.
Time of treatment:1st treatment : February 2018 / 2nd treatment : January 2019.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient took several medications with very mild relief. Her mother found out about Neridronate being available in Italy, but she was skeptical because the medication was not available in USA. Following a worsening of her daughter conditions she decided that it was worth giving it a chance. The results were so good that the patient decided to take it a second time, to get more improvements.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)
See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)

Daily Report


DAY 1: Arrival at the Venice airport, greeted by her Patient Manager, followed by check-in at her Hotel in Verona. Briefing focused on next days.

DAY 2: Morning meeting with her Patient Manager, rest day.

DAY 3: Morning pick-up by her Patient Manager, visit with the Rheumatologist Professor, 1st Neridronate infusion.

DAY 4: Morning pick-up by her Patient Manager, 2nd Neridronate infusion, visit of Verona.

DAY 5: Morning pick-up by her Patient Manager, 3rd Neridronate infusion.

DAY 6: Morning pick-up by her Patient Manager, 2nd visit with the Rheumatologist Professor and last Neridronate infusion.

DAY 7: Morning pick-up by her Patient Manager, day trip to Vicenza.

DAY 8: Morning pick-up by her Patient Manager, day trip to Garda Lake.

DAY 9: Morning meeting with Patient Manager, rest day.

DAY 10: Morning pick-up by her Patient Manager, drop-off at Venice airport.

Follow up

MARCH 2018 (1 month after first Neridronate treatment): the patient feels better, she is not using the wheelchair anymore and she rides her motor bike again.

JUNE/JULY 2018 (3 months after first Neridronate treatment): the patient feels much better, pain is lower and bearable. She is back to Italy for a tour of Rome and Pompei, she can walk and enjoy it.

JANUARY 2019 (10 months after first Neridronate treatment): the patient feels well but she is starting a very busy and stressful studies program. Since she is worried that it may trigger pain again and she wishes to improve the good results of the first treatment, she is back to Italy for the second Neridronate treatment.


Very few patients have requested a second treatment to reach biggest results and booster its efficacy. In some cases, the second treatment may be after a new injury that triggers the disease again. When it happens there is no problem in undergoing the Neridronate treatment twice, since it has been clearly shown that it does not bring any heavy side effects on the body.
This patient has seen good results from both her treatments and can appreciate lower and bearable pain. She is back to doing sports which she loves!

This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.